Drug profile · INN
bevacizumab
KYOMARC
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
bevacizumab (KYOMARC) is an FDA-listed pharmaceutical active ingredient. Associated with Outlook Therapeutics NL B. V.. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
INN bevacizumab
Brand KYOMARC
Route INTRAVENOUS
Formulation VIAL
ATC code L01FG01
Originator Outlook Therapeutics NL B. V.
Frequently asked questions
What is bevacizumab?
bevacizumab (KYOMARC) is an FDA-listed pharmaceutical active ingredient. Associated with Outlook Therapeutics NL B. V.. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for bevacizumab?
KYOMARC is a marketed brand name for bevacizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bevacizumab?
bevacizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.